HER2-driven mammary tumorigenesis enhances bioenergetics despite reductions in mitochondrial content

We comprehensively assessed the bulk tumor and mitochondrial metabolic phenotype in murine HER2-driven mammary cancer tumors and benign mammary tissue. Mitochondrial bioenergetics were enhanced in tumors despite reductions in mitochondrial content. Overall design: Murine MMTV-Neu-NDL-YD5 HER2-driven tumors and benign mammary tissue were compared (no treatment).